Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183

Results For "pharma"

4997 News Found

GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly
Clinical Trials | February 19, 2026

GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly

The data highlights its RSV vaccine cuts hospitalizations in older adults


GSK’s Exdensur wins EU nod for severe asthma
News | February 19, 2026

GSK’s Exdensur wins EU nod for severe asthma

The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen


Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI
Digitisation | February 19, 2026

Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI

Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care


Pfizer’s BRAFTOVI regimen shows major breakthrough in aggressive colorectal cancer
Clinical Trials | February 18, 2026

Pfizer’s BRAFTOVI regimen shows major breakthrough in aggressive colorectal cancer

BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC


LEX Diagnostics gets FDA nod and CLIA waiver for ultra-fast VELO system
News | February 18, 2026

LEX Diagnostics gets FDA nod and CLIA waiver for ultra-fast VELO system

The VELO system supports multiplex testing for Influenza A, Influenza B, and COVID-19, producing PCR results in six to ten minutes


FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma
Drug Approval | February 18, 2026

FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma

The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma


Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff
News | February 17, 2026

Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff

Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem


Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer
Clinical Trials | February 17, 2026

Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer

The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease